Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin in pediatric CD22-positive relapsed or refractory acute lymphoblastic leukemia
NL-OMON60313Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) and B-cell malignancy (7 arms), sponsored by Erasmus MC. Primary endpoints: Dose-limiting toxicities during first cycle, Overall response rate and 3 more. Started Jan 2017; status: active, not recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)B-cell malignancy
Beyond the preview
Go deeper on NL-OMON60313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60313.